ILO Home
Go to the home page
Site map | Contact us Français | Español

CISDOC database

Document ID (ISN)102846
CIS number 03-1809
ISBN(s) 92-832-1266-5
Year 1996
Convention or series no. IARC Monographs 66
World Health Organization (WHO)
Title IARC monographs on the evaluation of carcinogenic risks to humans - Some pharmaceutical drugs
Bibliographic information World Health Organization, Distribution and Sales Service, 1211 Genève 27, Switzerland, International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon Cedex 08, France 1996. iv, 514p. Illus. Bibl.ref. Index. Price: CHF 80.00.
Abstract This criteria document evaluates the following pharmaceutical compounds with respect to their carcinogenicity in humans: benzodiazepines and related compounds and phenytoin (diazepam, doxefazepam, estazolam, oxazepam, prazepam, ripazepam, temazepam, phenytoin); anti-oestrogenic compounds (droloxifene, tamoxifene, toremifene); hypolipidaemic drugs (clofibrate, gemfibrozil). Tamoxifene is classified in group 1 (carcinogenic in humans). Oxazepam and phenytoin are classified in group 2B (possibly carcinogenic in humans). All others fall under group 3 (not classifiable as to their carcinogenicity in humans).
Descriptors (primary) pharmaceutical products; WHO; carcinogenic effects; benzodiazepines; hazard evaluation; IARC
Descriptors (secondary) mutagenic effects; literature survey; diazepam; oxazepam; criteria document; phenytoin; cholesterol; epidemiologic study; classification; oestrogens
Document type E - Books, reports, proceedings
Country / State or ProvinceFrance
Subject(s) Toxic and dangerous substances
Broad subject area(s) Chemical safety
Browse category(ies) Heterocyclic compounds
IARC Monographs
Genetic factors in reaction to exposures
Risk evaluation